Abstract 12836: Usefulness of Serum Levels of Adipocytokines and Estimated Δ-5 Desaturase Activity as Biomarkers Predicting Hepatic Steatosis in Patients With Coronary Artery Disease on Statin Therapy
Introduction: Nonalcoholic fatty liver disease (NAFLD) is closely linked to obesity or type 2 diabetes mellitus, which are risk factors for coronary artery disease (CAD), and also includes non-alcoholic steatohepatitis that often develops life-threatening liver cirrhosis. Imaging tests for NAFLD are more sensitive than liver biochemistries, but expensive and cumbersome as screening tests. An establishment of biomarkers for NAFLD is important for prevention of fatal liver diseases in CAD patients.
Hypothesis: Serum levels of adipocytokines/adipokines and estimated Δ-5 desaturase (D5D) activity may be useful biomarkers predicting NAFLD in patients with CAD.
Methods: A cross-sectional study was conducted on 127 patients with CAD on statin therapy. Dihomo-γ-linolenic acid (DGLA) and arachidonic acid (AA) in serum total lipids were measured by gas chromatography, and D5D activity was estimated by AA to DGLA ratio. Serum levels of adiponectin (Apn), leptin, resistin, visfatin and plasminogen activator inhibitor (PAI)-1, were determined by the respective ELISA. Abdominal computed tomography (CT) measured CT attenuation for liver (L-CTA) to estimate lipid content, and subjects with L-CTA <50 HU were defined as NAFLD.
Results: Simple linear regressions revealed that L-CTA was significantly correlated with serum levels of Apn, leptin and D5D activity (p < 0.01, p = 0.03 and p < 0.001, respectively), but not with those of resistin, visfatin or PAI-1. In multivariate logistic analysis among three factors consisting of a low Apn level: < 6.8 μg/mL, a high leptin level: ≥ 3.4 ng/mL and a low D5D activity: ≤ 5.2 (the cutoff points were defined via ROC analysis against NAFLD), NAFLD was significantly associated with a high leptin level and a low D5D activity (adjusted odds ratio [OR]: 4.9, 95% confidence interval [CI]: 1.5-20) and OR: 15.6, 95%CI: 2.9-290, respectively), but weakly with a low Apn level (OR: 1.9, 95%CI: 0.6-6.5). A combination of these factors showed a strong association with NAFLD (area under the ROC curve: 0.84, p < 0.0001).
Conclusions: Serum levels of Apn, leptin and estimated D5D activity were significantly correlated with hepatic lipid content, and incrementally predict the presence of NAFLD in patients with CAD on statin therapy.
Author Disclosures: M. Matsuda: None. R. Tamura: None.
- © 2016 by American Heart Association, Inc.